AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...

Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33 (IL-33), an alarmin cytokine. This targeted approach is expected to reduce airway inflammation and ...

AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in chronic ...

People living with HIV face a greater risk of developing lung diseases at a much younger age, even if they have never smoked.

Quitting smoking and avoiding vaping may be crucial steps in managing COPD, as these habits expose your lungs to irritants that cause further damage. Quitting may slow the disease’s progression and ...

Doctors use a combination of methods, including reviewing medical history and spirometry, to diagnose COPD and assess lung damage. Blood tests and genetic testing can help determine the severity and ...

Increased severity of chronic obstructive pulmonary disease (COPD) was associated with an increased risk of mortality and hospitalization in patients with heart failure, according to a recent study ...

Laughing Water Capital highlights Theravance Biopharma as a special situation with significant upside potential. Read the ...

COPD, short for chronic obstructive pulmonary disease, is linked to a heightened risk of lung cancer in people who have never smoked. COPD, short for chronic obstructive pulmonary disease, is linked ...